Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.420
-0.450 (-9.24%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$992,377
Profits / Employee
-$2,640,793
Market Cap
103.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Sep 30, 2022 | 6 | 0 | - |
| Jun 30, 2022 | 6 | - | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| Alps Group | 93 |
| enGene Therapeutics | 82 |
| Verrica Pharmaceuticals | 76 |
| Alpha Cognition | 71 |
| Vivani Medical | 42 |
| Black Diamond Therapeutics | 21 |
| Cognition Therapeutics | 14 |
COYA News
- 1 day ago - Coya Therapeutics initiated with a Buy at Roth Capital - TheFly
- 10 days ago - Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Business Wire
- 24 days ago - Coya Therapeutics Proxy statement: Proxy filing - Filings
- 24 days ago - Coya Therapeutics Proxy statement: Proxy filing - Filings
- 25 days ago - Coya Therapeutics granted FDA Fast Track Designation for COYA 302 - TheFly
- 25 days ago - Coya Therapeutics reports Q1 EPS (32c), consensus (39c) - TheFly
- 25 days ago - Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
- 25 days ago - Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire